Dehydroxymethylepoxyquinomicin (DHMEQ)—The NF-κB inhibitor DHMEQ causes apoptotic death of thyroid carcinoma cells and blocks tumor formation in nude mice [86], and reduces spheres formation in ATC cell lines without affecting their survival; and, if used in combination with the STAT3 inhibitor STA-21, the effect is synergistic and additive [23]. Here, NFKB1 is linked to thyroid gland carcinoma.